前期研究发现HLA-Ⅰ类分子多态性与维吾尔族EB病毒(EBV)阳性霍奇金淋巴瘤(HL)的CTL应答反应有关，而HLA-Ⅱ类分子DP作为EBV gp42受体，其多态性在HL的发生、发展中更具有重要作用，故我们提出EBV可能通过gp42介导的HLA-DPB1相关性免疫逃逸参与HL发病的假说。本研究利用PCR-SBT技术筛选与维吾尔族HL相关的HLA-DPB1亚型，采用多层次(淋巴细胞系、PBMC、个体)和多手段(FACS、IHC、FQ-PCR)相结合的方法，观察上述筛选出的HLA-DPB1亚型对gp42介导的EBV感染的影响，进而探讨sgp42抑制CD4+T细胞免疫应答过程中，不同HLA-DPB1亚型免疫贡献的差异，揭示维吾尔族EBV阳性HL高发与HLA-DPB1特异性多态分布之间的内在联系，为EBV免疫逃逸及HL发病机制提供新的线索，并为研制维吾尔族HL防治性疫苗奠定实验基础。

Previous studies have found that human leukocyte antigen (HLA) class Ⅰ molecular polymorphisms involved in CTL response of Uyghur epstein-barr virus (EBV) -positive Hodgkin's lymphomas (HL), while HLA class Ⅱ molecular DP, as EBV-gp42 receptor, plays more important role in the occurrence and development of HL. We hypothesise that EBV involves in HL pathogenesis via EBV-gp42 mediated HLA-DPB1 restrictive immune escape. So PCR-SBT will be carried out to analyze HLA DPB1 genotype related to Uyghur HL. On this basis, methods included FACS、IHC、FQ-PCR will be used to investigate the role of HLA-DPB1 polymorphism in EBV infection on multi-level (lymphoid cell lines and PBMC and individual). Meanwhile, the effects of HLA-DPB1 SNP on inhibition of CD4+T immune response by soluble gp42 secreted by EBV infected cells are also further investigated. Results from these innovative studies should allow us to reveal the relation of HLA DPB1 SNP and Uyghur EBV positive HL. Moreover our study will contribute to provide new clues to the pathogenesis of HL and EBV immune escape laying foundation to the development of vaccine for Uyghur HL.